

# Manish R Patel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8499144/publications.pdf>

Version: 2024-02-01

49  
papers

2,581  
citations

430874

18  
h-index

233421

45  
g-index

49  
all docs

49  
docs citations

49  
times ranked

4325  
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	7.0	74
2	The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2916.	4.1	8
3	Exceptional response to afatinib in a patient with persistent G719A <i>EGFR</i> -mutant NSCLC. <i>Lung Cancer Management</i> , 2022, 11, LMT54.	1.5	3
4	4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer. <i>Investigational New Drugs</i> , 2021, 39, 636-643.	2.6	5
5	Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110044.	1.3	13
6	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	1.6	74
7	Animated patient's guide to lung cancer enables shared decisions and improves health outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18634-e18634.	1.6	0
8	Cytomegalovirus infection in malignant pleural mesothelioma. <i>PLoS ONE</i> , 2021, 16, e0254136.	2.5	4
9	957...NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study. , 2021, 9, A1007-A1007.		3
10	Entrectinib in <i>ROS1</i> fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	10.7	303
11	Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon- $\beta$ in Preclinical Models of Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2020, 13, 100782.	3.7	14
12	Nutrition Status and Health-Related Quality of Life Among Outpatients With Advanced Head and Neck Cancer. <i>Nutrition in Clinical Practice</i> , 2020, 35, 1129-1137.	2.4	24
13	Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 425-432.	2.3	6
14	Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.3	3
15	Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFN $\beta$ -NIS (VV1) oncolytic virus in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3090-3090.	1.6	10
16	Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i> -fusion positive ( <i>NTRK</i> -fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	1.6	33
17	Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFN $\beta$ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3161-TPS3161.	1.6	1
18	Immune Checkpoint Inhibitors in <i>ROS1</i> -Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases. <i>Journal of Thoracic Oncology</i> , 2019, 14, e165-e167.	1.1	12

#	ARTICLE	IF	CITATIONS
19	A review of avelumab in locally advanced and metastatic bladder cancer. Therapeutic Advances in Urology, 2019, 11, 175628721882348.	2.0	15
20	Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer. Cancer Gene Therapy, 2019, 26, 157-165.	4.6	9
21	JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Therapy, 2019, 26, 411-418.	4.6	60
22	Impact of antibiotics and proton pump inhibitors on clinical outcomes of immune check point blockers in advanced non-small cell lung cancers and metastatic renal cell cancer.. Journal of Clinical Oncology, 2019, 37, e20520-e20520.	1.6	12
23	Clinical predictors of efficacy for immune checkpoint inhibition in lung cancer patients.. Journal of Clinical Oncology, 2019, 37, e20600-e20600.	1.6	1
24	Immunotherapy for thoracic oncology gone viral. Immunotherapy, 2018, 10, 383-390.	2.0	1
25	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncology, The, 2018, 19, 694-704.	10.7	310
26	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncology, The, 2018, 19, 51-64.	10.7	491
27	4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. Investigational New Drugs, 2018, 36, 217-229.	2.6	9
28	ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.. Journal of Clinical Oncology, 2018, 36, 6052-6052.	1.6	1
29	Viroimmunotherapy of Thoracic Cancers. Biomedicines, 2017, 5, 2.	3.2	11
30	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase 1b Study. Journal of Clinical Oncology, 2017, 35, 2117-2124.	1.6	538
31	Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma. Oncotarget, 2017, 8, 63096-63109.	1.8	7
32	Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy—a report of two cases. , 2016, 4, 80.		80
33	Malnutrition Identified by the Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition Consensus Criteria and Other Bedside Tools Is Highly Prevalent in a Sample of Individuals Undergoing Treatment for Head and Neck Cancer. Journal of Parenteral and Enteral Nutrition, 2016, 42, 014860711667226.	2.6	29
34	Endometrial Metastasis of Lung Adenocarcinoma: A Report of Two Cases. American Journal of Case Reports, 2015, 16, 296-299.	0.8	15
35	Genetic Engineering of Oncolytic Viruses for Cancer Therapy. , 2015, , 261-279.		3
36	Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma. Genes and Cancer, 2015, 6, 144-152.	1.9	27

#	ARTICLE	IF	CITATIONS
37	Vesicular stomatitis virus expressing interferon- $\beta$ is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33165-33177.	1.8	87
38	Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives. <i>Anticancer Research</i> , 2015, 35, 5211-7.	1.1	4
39	Measles Vaccine Strains for Virotherapy of Non-Small-Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1101-1110.	1.1	27
40	Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. <i>Investigational New Drugs</i> , 2014, 32, 598-603.	2.6	21
41	An Absolute Obstacle: Cardiac Metastasis of Synovial Sarcoma. <i>American Journal of Medicine</i> , 2014, 127, 390-392.	1.5	2
42	Oncolytic virus therapy for cancer: the first wave of translational clinical trials. <i>Translational Research</i> , 2013, 161, 355-364.	5.0	87
43	Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1142-1147.	1.1	12
44	Targeting Eukaryotic Translation in Mesothelioma Cells with an eIF4E-Specific Antisense Oligonucleotide. <i>PLoS ONE</i> , 2013, 8, e81669.	2.5	32
45	Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation. <i>International Journal of Oncology</i> , 2012, 40, 577-82.	3.3	7
46	Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. <i>Investigational New Drugs</i> , 2012, 30, 1443-1448.	2.6	15
47	Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. <i>Investigational New Drugs</i> , 2010, 28, 20-25.	2.6	28
48	Ras Pathway Activation in Malignant Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2007, 2, 789-795.	1.1	31
49	Effects of Insulin-Like Growth Factor-1 Receptor Inhibition in Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2006, 82, 996-1002.	1.3	19